 |
|
|
| |
Healthcare resource use (HCRU) and cost impact of potential drug-drug interactions (DDIs) among HCV patients receiving direct-acting antivirals (DAAs) concomitantly with antipsychotic drugs in the US
|
| |
| |
EASL 2025 May 7-10 Amsterdam
Dilip Makhija,1 Thomas Debray,2 Candido Hernández3
1Gilead Sciences, Parsippany, United States of America, 2Smart Data Analysis and Statistics, Utrecht, Netherlands, 3Gilead Sciences, S.L.U, Madrid, Spain
|
| |
|
|
|
|
|
